Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Apogee Therapeutics, Inc. Banner

Apogee Therapeutics, Inc.

APGE Stock Analysis

Page title

Section title

About Apogee Therapeutics, Inc.

Biotechnology
Healthcare

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics, Inc. Key Metrics

Market Cap
$3B
52 Weeks Low
$14.19
52 Weeks High
$72.29
P/B
3.90x
P/E
-25.44x
P/S
0x

Upcoming Events

    APGE Analyst Forecasts

    ‌
    ‌

    APGE Financials

    APGE Income Statement Key Metrics

    • Revenue(TTM)0
    • Gross Profit(TTM)-65,000
    • EBITDA(TTM)-140.23 M
    • Net Income(TTM)-118.49 M
    • EPS Diluted(TTM)-2.2800000000000002

    Decode APGE's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    APGE earnings and revenue history

    APGE Return on Equity

    See how efficiently APGE generates profit for it's shareholders.

    0%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity Growth

    APGE's Return on Equity has grown significantly over the past 10 years, increasing by over 52.98%.

    APGE Revenue Growth

    See how APGE has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    APGE's revenue has shown poor growth over the past 10 years, increasing by only 0%.